Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 14/20 | 0.34 |
| ▸ | FDPS | P14324 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6702684 | 0.90 | BACE1 (0.41) | BACE1IDO1FDPS | |
| SCHEMBL4033343 | 0.86 | BACE1 (0.40) | BACE1 | |
| SCHEMBL7234154 | 0.85 | CYP3A4 (0.41) | BACE1ALDH1A1 | |
| SCHEMBL15389825 | 0.84 | BACE1 (0.42) | BACE1IDO1 | |
| SCHEMBL1474688 | 0.83 | DUT (0.35) | BACE1IDO1FDPSALDH1A1 | |
| SCHEMBL7747937 | 0.83 | FDPS (0.33) | BACE1IDO1FDPSALDH1A1 | |
| SCHEMBL29823262 | 0.83 | DUT (0.35) | BACE1IDO1FDPSALDH1A1 | |
| SCHEMBL21587953 | 0.82 | BACE1 (0.44) | BACE1IDO1 | |
| SCHEMBL24668606 | 0.81 | ALDH1A1 (0.36) | IDO1FDPSALDH1A1 | |
| SCHEMBL8069572 | 0.80 | DUT (0.39) | BACE1IDO1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4121415-B1 | INHIBITORS OF CYTOKININ OXIDASE DERIVED FROM 1-[2-(HYDROXYALKYL)PHENYL]-3-YLUREA, USE THEREOF AND PREPARATIONS CONTAINING THESE DERIVATIVES | UNIV PALACKEHO (CZ) | 2024-02-07 | — | — | EP | disclosed |
| US-11655269-B2 | Prodrug-type anticancer agent using cancer-specific enzymatic activity | THE UNIVERSITY OF TOKYO (JP) | 2023-05-23 | — | — | US | disclosed |
| US-11655269-B2 | Prodrug-type anticancer agent using cancer-specific enzymatic activity | THE UNIVERSITY OF TOKYO (JP) | 2023-05-23 | — | — | US | disclosed |
| EP-4121415-A1 | INHIBITORS OF CYTOKININ OXIDASE DERIVED FROM 1-[2-(HYDROXYALKYL)PHENYL]-3-YLUREA, USE THEREOF AND PREPARATIONS CONTAINING THESE DERIVATIVES | Univerzita Palackého v Olomouci (CZ) | 2023-01-25 | — | — | EP | disclosed |
| WO-2021185391-A1 | INHIBITORS OF CYTOKININ OXIDASE DERIVED FROM 1-[2-(HYDROXYALKYL)PHENYL]-3-YLUREA, USE THEREOF AND PREPARATIONS CONTAINING THESE DERIVATIVES | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2021-09-23 | — | — | WO | disclosed |
| US-20200399305-A1 | PRODRUG-TYPE ANTICANCER AGENT USING CANCER-SPECIFIC ENZYMATIC ACTIVITY | THE UNIVERSITY OF TOKYO (JP) | 2020-12-24 | — | — | US | disclosed |
| WO-2019172210-A1 | PRODRUG-TYPE ANTICANCER AGENT USING CANCER-SPECIFIC ENZYMATIC ACTIVITY | 国立大学法人 東京大学 | 2019-09-12 | — | — | WO | disclosed |
| EP-1252144-B1 | SUBSTITUTED GLUTARIMIDES AND USE THEREOF IL-12 PRODUCTION INHIBITORS | GRUENENTHAL GMBH (DE) | 2009-12-09 | — | — | EP | disclosed |
| WO-2009011850-A2 | NOVEL THERAPEUTIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2009-01-22 | — | — | WO | disclosed |
| EP-0848004-B1 | PYRROLIDINE DERIVATIVES HAVING PHOSPHOLIPASE A2 INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2003-04-02 | — | — | EP | disclosed |
| EP-1252144-A1 | SUBSTITUTED GLUTARIMIDES AND USE THEREOF IL-12 PRODUCTION INHIBITORS | Grünenthal GmbH (DE) | 2002-10-30 | — | — | EP | disclosed |
| WO-2001053261-A1 | SUBSTITUTED GLUTARIMIDES AND USE THEREOF IL-12 PRODUCTION INHIBITORS | Grünenthal GmbH (DE) | 2001-07-26 | — | — | WO | disclosed |
| EP-1067130-A1 | TRIAZOLO DERIVATIVES AND CHEMOKINE INHIBITORS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | TORAY INDUSTRIES, INC. (JP) | 2001-01-10 | — | — | EP | disclosed |
| US-5955616-A | PROSTAGLANDIN INHIBITORS | SHIONOGI & CO., LTD. (JP) | 1999-09-21 | — | — | US | disclosed |
| EP-0848004-A1 | PYRROLIDINE DERIVATIVES HAVING PHOSPHOLIPASE A2 INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 1998-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655269-B2 | Prodrug-type anticancer agent using cancer-specific enzymatic activity | GUSB, NTPCR, FOLH1 | BACE1 1943/4885IDO1 1628/4885FDPS 1187/4885 |
| US-20200399305-A1 | PRODRUG-TYPE ANTICANCER AGENT USING CANCER-SPECIFIC ENZYMATIC ACTIVITY | GUSB, NTPCR, FOLH1 | BACE1 1943/4885IDO1 1628/4885FDPS 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.